FTY720 is a novel, once-daily, oral treatment in worldwide Phase III clinical development for the treatment of relapsing-remitting MS, the form of the disease that affects approximately 85% of ...

FTY720 is an immune modulator and a synthetic analogue of sphingosine 1-phosphate (S1P), activated S1P receptors and is effective in experimental models of transplantation and autoimmunity.

Overall, FTY720 was well tolerated: treatment was discontinued because of AEs in four, five and eight patients receiving placebo, or FTY720 1.25 and 5 mg, respectively, during the 6-month core study.

A study aiming to deliver Fingolimod (FTY720) loaded polymer scaffolds to enhance oral wound healing by modulating pro-regenerative immune cell migration associated with improved vascularization ...

FTY720 was chosen for these studies because it does not directly target the BCR-ABL kinase, which in individuals with CML-BC and ALL is resistant to kinase inhibitors such as imatinib (Gleevec).

Novartis SA said one patient died and another developed a serious infection in tests of its FTY720 multiple sclerosis treatment. ``Novartis was recently notified of two infection-related incidents ...

FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis) was a double-blind, placebo-controlled study involving 1,272 patients in 22 countries to assess the ...

FTY720 is an immune-modulating drug that binds to a receptor site on immune cells, sequestering them in the lymph nodes. As a result, FTY720 reduces their ability to cause damage associated with ...

A study aiming to deliver Fingolimod (FTY720) loaded polymer scaffolds to enhance oral wound healing by modulating pro-regenerative immune cell migration associated with improved vascularization ...

Novartis AG's <NOVN.VX> once-daily FTY720 pill reduced the number of attacks suffered by patients with multiple sclerosis (MS) after three years, according to data presented on Tuesday.

and , Clinical Neuroinmunology Unit, Multiple Sclerosis Center of Catalonia (CEM-Cat), Vall d'Hebron University Hospital, Edif. EUI, Planta 2, Pg. Vall d'Hebron, 119 ...